XenoPort Announces Presentations of Data for Arbaclofen Placarbil and XP13512 at the Associated Professional Sleep Society Meeting

SANTA CLARA, Calif.--(BUSINESS WIRE)--Jun 7, 2010 - XenoPort announced today that data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the Associated Professional Sleep Society meeting in San Antonio, Texas. The following data will be presented:

Arbaclofen placarbil, also known as XP19986
GERD

 

  • Arbaclofen Placarbil Improves Sleep Quality in Patients with Proton Pump Inhibitor (PPI) - Responsive Gastroesophageal Reflux Disease (GERD)
    Session: P15 Medical Disorders and Their Effects on Sleep: June 7, 2010, 10:30 a.m. - 12:30 p.m. CDT
    Poster #: 270

XP13512 (gabapentin enacarbil)
Moderate-to-Severe Primary Restless Legs Syndrome

 

  • A Randomized, Crossover Polysomnography Study of Gabapentin Enacarbil In Subjects with Moderate-to-Severe Primary Restless Legs Syndrome and Associated Sleep Disturbance
    Oral Session: O15: Treatment Advances in Restless Legs Syndrome: June 8, 2010, 2:15 p.m. – 2:30 p.m. CDT
  • Subjective Post-Sleep Diary Findings from a Polysomnography Study of Gabapentin Enacarbil in Subjects with Primary Restless Legs Syndrome and Associated Sleep Disturbance
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
    Poster #: 261
  • An Open-Label, 52-Week Extension Study Assessing Tolerability and Efficacy of Gabapentin Enacarbil in Subjects with Primary Restless Legs Syndrome
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
    Poster #: 262
  • Population Pharmacokinetic-Pharmacodynamic Relationship of Gabapentin after Administration of Gabapentin Enacarbil in Subjects with Restless Legs Syndrome
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
    Poster #: 263
  • Effects of Gabapentin Enacarbil on Quality of Life, Mood, and Function in Subjects with Restless Legs Syndrome (RLS)
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
    Poster #: 264
  • Gabapentin Enacarbil Maintains Improvements in Sleep During Long-term Treatment in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
    Poster #: 265
  • An Evaluation of Restless Legs Syndrome Symptom Augmentation in Subjects Treated with Gabapentin Enacarbil for 12 weeks: Secondary Integrated Analyses from Two Studies
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
    Poster #: 266
  • Gabapentin Enacarbil Relieves the Pain Associated with Restless Legs Syndrome (RLS)
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
    Poster #: 267
  • Gabapentin Enacarbil Improves Restless Legs Syndrome (RLS) Symptoms and Subjective Measures of Sleep in Subjects With Primary RLS With and Without Severe Sleep Disturbance: Secondary Analyses from Two Studies
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
    Poster #: 268

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in collaboration with Astellas Pharma Inc. and GlaxoSmithKline. XenoPort's product candidates are being studied for the potential treatment of moderate-to-severe primary restless legs syndrome, neuropathic pain, migraine headaches, gastroesophageal reflux disease, spasticity and Parkinson's disease.

XenoPort is a registered trademark of XenoPort, Inc.

XNPT2C

 

Contact: XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com

 

 

Posted: June 2010

View comments

Hide
(web5)